Cibc World Market Inc. Takes Position in DaVita Inc. $DVA

Cibc World Market Inc. acquired a new stake in shares of DaVita Inc. (NYSE:DVA) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 13,755 shares of the company’s stock, valued at approximately $3,060,000.

Several other large investors also recently bought and sold shares of the business. Root Financial Partners LLC raised its position in DaVita by 128.0% in the 1st quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock worth $29,000 after buying an additional 105 shares during the last quarter. Caitlin John LLC purchased a new stake in shares of DaVita during the 4th quarter valued at about $34,000. Sankala Group LLC bought a new stake in shares of DaVita in the fourth quarter worth approximately $39,000. Canada Pension Plan Investment Board purchased a new position in shares of DaVita during the second quarter valued at approximately $43,000. Finally, Kestra Advisory Services LLC purchased a new position in shares of DaVita during the fourth quarter valued at approximately $45,000. 90.12% of the stock is currently owned by institutional investors.

DaVita Price Performance

Shares of NYSE:DVA opened at $180.34 on Thursday. The company has a market capitalization of $11.51 billion, a P/E ratio of 14.76, a P/E/G ratio of 0.59 and a beta of 0.88. DaVita Inc. has a 1-year low of $101.00 and a 1-year high of $247.49. The firm’s 50 day simple moving average is $213.07 and its two-hundred day simple moving average is $182.80.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.88 by $0.14. The firm had revenue of $3.55 billion during the quarter, compared to analysts’ expectations of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. The company’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period in the prior year, the company posted $2.95 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, sell-side analysts anticipate that DaVita Inc. will post 14.57 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other DaVita news, insider Kathleen Alyce Waters sold 15,405 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the sale, the insider owned 109,194 shares in the company, valued at approximately $22,756,029.60. This represents a 12.36% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 1.90% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on DVA. Zacks Research cut shares of DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Truist Financial decreased their target price on shares of DaVita from $250.00 to $215.00 and set a “hold” rating for the company in a research note on Friday, August 7th. Raymond James Financial set a $220.00 price objective on DaVita in a report on Friday, August 7th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $265.00 price objective on shares of DaVita in a research report on Wednesday, August 5th. Finally, UBS Group increased their target price on DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a report on Friday, July 10th. Four research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $221.75.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.